Source: Yahoo Finance
Moderna, Inc. MRNA) announced that it has signed a supply agreement with the European Commission for 80 million doses of its coronavirus vaccine candidate, mRNA-1273. The company has been in advanced discussions for this deal with the European Commission since August. Per the agreement, the European Commission has an option to purchase up to an additional 80 million doses of mRNA-1273.
Moderna expects to start delivery of the vaccine, if it is approved, as early as the first quarter of 2021. Please note that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) started rolling review of its marketing authorization application for mRNA-1273 earlier this month.
The company has been actively engaged in securing supply deals for the candidate and has signed agreements with several countries including the United States, Japan, Canada, Japan and the United Kingdom. The company has also enough manufacturing capabilities to support supply of mRNA-1273 to these countries and more.